Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Lin, Min ^a   DiVito, Melinda M ^a,b   Merajver, Sofia D ^a   Boyanapalli, Madanamohan ^c   van Golen, Kenneth L ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Caveolin 1; Cell migration; MAPK; Metastasis; Pancreatic cancer; RhoC GTPase

Indexed keywords

ACTIN; CAVEOLIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC GUANOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN DERIVATIVE; METHYL BETA CYCLODEXTRIN; METHYL-BETA-CYCLODEXTRIN; RHOC PROTEIN, HUMAN;

ARTICLE; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; CANCER INVASION; CELL MOTION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

BETA-CYCLODEXTRINS; CAVEOLIN 1; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; RHO GTP-BINDING PROTEINS;

EID: 26844439985     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-4-21     Document Type: Article

References (58)

1. Fujimoto T, Kogo H, Nomura R, Une T: Isoforms of caveolin-1 and caveolar structure. J Cell Sci 2000, 113 Pt 19:3509-3517.
2. Okamoto T, Schlegel A, Scherer PE, Lisanti MP: Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998, 273:5419-5422.
3. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP: Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 1996, 271:9690-9697.
4. Gingras D, Gauthier F, Lamy S, Desrosiers RR, Beliveau R: Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains. Biochem Biophys Res Commun 1998, 247:888-893.
5. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG, Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 2000, 275:20717-20725.
6. Fiucci G, Ravid D, Reich R, Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002, 21:2365-2375.
7. Lu Z, Ghosh S, Wang Z, Hunter T: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4:499-515.
8. Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 2004, 23:7893-7897.
9. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP: Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004, 279:51630-51646.
10. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM: Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002, 161:1647-1656.
11. Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M: Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol 2004, 172:718-722.
12. Bender FC, Reymond MA, Bron C, Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000, 60:5870-5878.
13. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002, 87:1140-1144.
14. Wu C, Butz S, Ying Y, Anderson RG: Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane. J Biol Chem 1997, 272:3554-3559.
15. Gleizes PE, Noaillac-Depeyre J, Dupont MA, Gas N: Basic fibroblast growth factor (FGF-2) is addressed to caveolae after binding to the plasma membrane of BHK cells. Eur J Cell Biol 1996, 71:144-153.
16. Bilderback TR, Grigsby RJ, Dobrowsky RT: Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae. J Biol Chem 1997, 272:10922-10927.
17. Li S, Couet J, Lisanti MP: Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996, 271:29182-29190.
18. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP: Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 1995, 270:15693-15701.
19. Raftopoulou M, Hall A: Cell migration: Rho GTPases lead the way. Dev Biol 2004, 265:23-32.
20. del Peso L, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C, Lacal JC: Rho proteins induce metastatic properties in vivo. Oncogene 1997, 15:3047-3057.
21. Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000, 406:532-535.
22. Carr KM, Bittner M, Trent JM: Gene-expression profiling in human cutaneous melanoma. Oncogene 2003, 22:3076-3080.
23. Marionnet C, Lalou C, Mollier K, Chazal M, Delestaing G, Compan D, Verola O, Vilmer C, Cuminet J, Dubertret L, Basset-Seguin N: Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development. Oncogene 2003, 22:3500-3505.
24. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003, 83:861-870.
25. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003, 9:2632-2641.
26. Shinto E, Tsuda H, Matsubara O, Mochizuki H: [Significance of RhC expression in terms of invasion and metastasis of colorectal cancer]. Nippon Rinsho 2003, 61 Suppl 7:215-219.
27. Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ: Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol 2003, 9:1950-1953.
28. Kondo T, Sentani K, Oue N, Yoshida K, Nakayama H, Yasui W: Expression of RHOC is associated with metastasis of gastric carcinomas. Pathobiology 2004, 71:19-25.
29. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M: Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998, 77:147-152.
30. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, Lemoine NR: Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002, 21:4587-4594.
31. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003, 63:2649-2657.
32. van Golen KL: Inflammatory Breast Cancer: Relationship between growth factor signaling and motility in aggressive cancers. Breast Cancer Research 2003, 5:174.
33. Lin M, van Golen KL: Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 2003.
34. Aktories K, Hall A: Botulinum ADP-ribosyltransferase C3: a new tool to study low molecular weight GTP-binding proteins. Trends Pharmacol Sci 1989, 10:415-418.
35. Aktories K, Braun U, Rosener S, Just I, Hall A: The rho gene product expressed in E. coli is a substrate of botulinum ADP-ribosyltransferase C3. Biochem Biophys Res Commun 1989, 158:209-213.
36. Couet J, Belanger MM, Roussel E, Drolet MC: Cell biology of caveolae and caveolin. Adv Drug Deliv Rev 2001, 49:223-235.
37. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP: Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997, 272:6525-6533.
38. Engelman JA, Zhang XL, Razani B, Pestell RG, Lisanti MP: p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem 1999, 274:32333-32341.
39. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP: Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998, 428:205-211.
40. van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD: Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis 2002, 19:301-311.
41. Yip-Schneider MT, Lin A, Marshall MS: Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 2001, 280:992-997.
42. Berger DH, Jardines LA, Chang H, Ruggeri B: Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res 1997, 69:199-204.
43. Ilangumaran S, Hoessli DC: Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem J 1998, 335 (Pt 2):433-440.
44. Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci U S A 1995, 92:1381-1385.
45. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997, 272:16374-16381.
46. Razani B, Schlegel A, Liu J, Lisanti MP: Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 2001, 29:494-499.
47. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC: Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001, 61:4386-4392.
48. Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY: The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med 2003, 32:461-467.
49. Bockhorn M, Roberge S, Sousa C, Jain RK, Munn LL: Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Res 2004, 64:2469-2473.
50. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 2003, 22:469-480.
51. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, Tsao MS: Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000, 157:1623-1631.
52. Liu N, Furukawa T, Kobari M, Tsao MS: Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 1998, 153:263-269.
53. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD: RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000, 2:418-425.
54. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD: RhoC GTase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000, 60:5832-5838.
55. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD: Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002, 160:579-584.
56. Evers EE, van der Kammen RA, ten Klooster JP, Collard JG: Rho-like GTPases in tumor cell invasion. Methods Enzymol 2000, 325:403-415.
57. Diekmann D, Hall A: In vitro binding assay for interactions of Rho and Rac with GTPase- activating proteins and effectors. Methods Enzymol 1995, 256:207-215.
58. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ: A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987, 38:137-147.